Halozyme Therapeutics, Inc. HALO
128.14 USD -0.48 (-0.37%)
Nov 4, 2026, 11:29 AM EST
126.86 Day range 130.81
61.23 52-week range 134.00
- YTD
- +90.40%
- 1 year
- +88.30%
Analyst view
Consensus: buy
Buy
Price target (mean) 108.89 -15.0% downside
Now 128.14
- Target (low)
- 79.00
- Target (mean)
- 108.89
- Target (high)
- 130.00
Ratings (0m) 9 7 buy · 2 hold · 0 sell
- Strong buy2
- Buy5
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 9
- 1 month ago 9
- 2 months ago 9
- 3 months ago 9
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 2.36 | 2.33 – 2.37 | 1.72 | +37.0% | 491.56M | +38.8% | 6 |
| Next quarter | 2.62 | 2.46 – 2.75 | -0.24 | +1193.3% | 537.59M | +19.0% | 6 |
| Current year | 8.84 | 8.65 – 8.98 | 4.15 | +113.1% | 1.88B | +34.7% | 6 |
| Next year | 10.69 | 10.11 – 11.35 | 8.84 | +20.9% | 2.10B | +11.7% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 3, 2026 | JP Morgan | Maintained | Neutral | Neutral |
| Oct 13, 2026 | TD Cowen | Maintained | Buy | Buy |
| Oct 8, 2026 | JP Morgan | Maintained | Neutral | Neutral |
| Oct 8, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 2, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 7, 2026 | Leerink Partners | Upgrade | Market Perform | Outperform |
| Aug 7, 2026 | TD Cowen | Maintained | Buy | Buy |
| Aug 7, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| Aug 7, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Aug 7, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jul 21, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 12, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Apr 29, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Feb 19, 2026 | Benchmark | Maintained | Buy | Buy |
| Feb 19, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Jan 8, 2026 | TD Cowen | Maintained | Buy | Buy |
| Dec 19, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 28, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 18, 2025 | Goldman Sachs | Maintained | Neutral | Neutral |
| Nov 4, 2025 | Citizens | Maintained | Market Outperform | Market Outperform |
| Oct 27, 2025 | JP Morgan | Maintained | Neutral | Neutral |
| Oct 20, 2025 | Morgan Stanley | Maintained | Overweight | Overweight |
| Oct 15, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 14, 2025 | Leerink Partners | Upgrade | Underperform | Market Perform |
| Oct 2, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 24, 2025 | Benchmark | Maintained | Buy | Buy |
| Sep 22, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 18, 2025 | Morgan Stanley | Maintained | Overweight | Overweight |
| Aug 7, 2025 | JP Morgan | Maintained | Neutral | Neutral |
| Aug 6, 2025 | JMP Securities | Maintained | Market Outperform | Market Outperform |